Read this company snapshot
Daily valuation snapshot
Molecular Partners AG American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $3.85
- Market capitalization (USD)
- $155,442,367.85
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.54
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research MOLN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research MOLN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing MOLN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $3.85 |
| Market capitalization (USD) | $155,442,367.85 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.54 |
No matching rows. Clear the filter to see all records.
Read MOLN's valuation metrics
Company size
Molecular Partners AG American Depositary Shares's recorded market capitalization is $155,442,367.85. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
MOLN's recorded price-to-book ratio is 1.54. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Molecular Partners AG American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about MOLN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow MOLN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.